natgillin/translations-raw huggingface dataset:
Brimica Genuair 340 mikrogram/12 mikrogram inhalationspulver aclidinium/formoterol fumaratdihydrat
Brimica Genuair 340 micrograms /12 micrograms inhalation powder aclidinium/formoterol fumarate dihydrate
Brimica Genuair 340/12 mikrogram inhalationspulver Aclidinium/formoterol fumaratdihydrat
Brimica Genuair 340/12 mcg inhalation powder Aclidinium/Formoterol fumarate dihydrate
Brimica Genuair 340/12 mikrogram inhalationspulver Aclidinium/formoterol fumaratdihydrat
Brimica Genuair 340/12 micrograms inhalation powder Aclidinium/Formoterol fumarate dihydrate
Brimica Genuair anvendes som vedligeholdelses- (langsigtet) behandling af KOL.
Brimica Genuair is used as a maintenance (long-term) treatment for COPD.
Brimica Genuair anvendes til voksne patienter, som lider af åndedrætsbesvær pga. en lungesygdom betegnet kronisk obstruktiv lungesygdom (KOL), hvor luftvejene og luftlommerne i lungerne beskadiges eller blokeres.
Brimica Genuair is used for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD), in which the airways and air sacs in the lungs become damaged or blocked.
Brimica Genuair bør anvendes med forsigtighed hos patienter med alvorlige hjerte-kar-sygdomme, krampesygdomme, thyrotoksikose og fæokromocytom.
Brimica Genuair should be used with caution in patients with severe cardiovascular disorders, convulsive disorders, thyrotoxicosis and phaeochromocytoma.
Brimica Genuair er et hvidt eller næsten hvidt pulver.
Brimica Genuair is a white or almost white powder.
Brimica Genuair er ikke beregnet til brug hos børn eller teenagere under 18 år.
Brimica Genuair is not for use in children or adolescents below 18 years of age.
Brimica Genuair forbedrede daglige symptomer på KOL, såsom ’kortåndethed’, ’symptomer i brystet’, ’hoste og spyt’ (vurderet ved E-RS totalscore) samt generelle symptomer om natten, generelle symptomer tidligt om morgenen og symptomer, der begrænsede aktiviteter tidligt om morgenen i forhold til placebo, aclidinium og formoterol, men forbedringerne var ikke altid statistisk signifikante.
Brimica Genuair improved daily symptoms of COPD such as ‘breathlessness’, ‘chest symptoms’, ‘cough and sputum’ (assessed by E-RS total score) as well as overall night-time symptoms, overall early morning symptoms and symptoms limiting early morning activities compared to placebo, aclidinium and formoterol but the improvements were not always statistically significant.
Brimica Genuair forsinkede desuden på statistisk signifikant vis tiden til første moderate eller svære exacerbation sammenlignet med placebo (risikoforhold=0,70; p=0,027).
In addition, Brimica Genuair statistically significantly delayed the time to first moderate or severe exacerbation compared to placebo (hazard ratio=0.70; p=0.027).
Brimica Genuair påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Brimica Genuair is unlikely to affect your ability to drive or use machines.
Brimica Genuair udviste en klinisk relevant forbedring i sygdomsspecifik helbredsstatus (vurderet ud fra St. Georges Respiratory Questionnaire [SGRQ]) i AUGMENT-studiet med en forbedring af samlet SGRQ score sammenlignet med placebo på -4,35 enheder (p <0,0001).
Brimica Genuair provided a clinically meaningful improvement in disease-specific health status (as assessed by the St. George’s Respiratory Questionnaire [SGRQ]) in study AUGMENT, with an improvement in the SGRQ total score compared to placebo of -4.35 units (p<0.0001).
Brimonidin metaboliseres hovedsageligt i leveren.
Brimonidine is extensively metabolised by the liver.
Brimonidin metaboliseres i udpræget grad af den hepatiske aldehyd-oxidase med dannelse af 2- oxobrimonidin, 3-oxobrimonidin og 2,3-dioxobrimonidin, som er hovedmetabolitterne.
Brimonidine is extensively metabolized by hepatic aldehyde oxidase with formation of 2-oxobrimonidine, 3- oxobrimonidine and 2,3-dioxobrimonidine being the major metabolites.
Brimonidin og dets metabolitter udskilles hovedsageligt i urinen.
Urinary excretion is the major route of elimination of brimonidine and its metabolites.
Brimonidin udviste ingen specielle reproduktions- eller udviklingsskader hos dyr.
Brimonidine did not present any special reproductive or developmental hazard in animal species.
Brimonidin-tartrat kan medføre okulære overfølsomhedsreaktioner.
Brimonidine tartrate may cause ocular allergic reactions.
Brimonidins proteinbinding er ikke undersøgt.
The protein binding of brimonidine has not been studied.
BRINAVESS 20 mg/ml koncentrat til infusionsvæske, opløsning vernakalanthydrochlorid
BRINAVESS 20 mg/ml concentrate for solution for infusion vernakalant hydrochloride
BRINAVESS 20 mg/ml, sterilt koncentrat vernakalanthydrochlorid
BRINAVESS 20 mg/ml sterile concentrate vernakalant hydrochloride
BRINAVESS afhjalp symptomerne fra atrieflimren i overensstemmelse med konvertering til sinusrytme.
BRINAVESS was shown to provide relief of atrial fibrillation symptoms consistent with conversion to sinus rhythm.
Brinavess anvendes til hurtigt at genoprette normal hjerterytme hos voksne patienter (18 år og derover), som for nylig er begyndt at have atrieflimren.
Brinavess is used to rapidly restore normal heart rhythm in adult patients (aged 18 years or over) who have recently started having atrial fibrillation.
BRINAVESS blev ikke fundet effektivt til konvertering af typisk primær atrieflagren til sinusrytme.
BRINAVESS was not found to be effective in converting typical primary atrial flutter to sinus rhythm.
Brinavess blev sammenlignet med placebo (en virkningsløs behandling) i to hovedundersøgelser, der omfattede 596 voksne med atrieflimren.
In two main studies involving 596 adults with atrial fibrillation, Brinavess was compared with placebo (a dummy treatment).
BRINAVESS bør anvendes med forsigtighed hos patienter, der får orale antiarytmika (klasse I og III) pga. begrænset erfaring.
BRINAVESS should be used with caution in patients on oral AADs (class I and III), due to limited experience.
BRINAVESS bør ikke gives til patienter, der tidligere har fået antiarytmika (klasse I og III) 4-24 timer før vernakalant pga. mangel på data.
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant due to lack of data.
BRINAVESS bør ikke gives til patienter, der tidligere har fået antiarytmika (klasse I og III) 4-24 timer før vernakalant pga. mangel på data.
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
BRINAVESS bør ikke gives til patienter, der tidligere har fået intravenøse antiarytmika (klasse I og III) 4-24 timer før vernakalant pga. manglende data.
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
BRINAVESS er blevet givet til patienter med ukorrigeret QT <440 ms uden øget risiko for torsades de pointes.
BRINAVESS has been administered to patients with an uncorrected QT less than 440 msec without an increased risk of torsade de pointes.
Brinavess er et koncentrat til fremstilling af en infusionsvæske, opløsning (intravenøst drop).
Brinavess is a concentrate that is made up into a solution for infusion (drip into a vein).
Brinavess må ikke anvendes til personer, som kan være overfølsomme (allergiske) over for vernakalanthydrochlorid eller andre af indholdsstofferne.
Brinavess should not be used in people who may be hypersensitive (allergic) to vernakalant hydrochloride or any of the other ingredients.
BRINAVESS må ikke bruges, hvis De bemærker partikelindhold eller misfarvning.
Do not administer BRINAVESS if you notice particulate matter or discolouration.
Brinavess må ikke gives inden for 30 dage efter at have haft akut koronarsyndrom (en gruppe af hjerteproblemer, der omfatter ustabil angina og hjerteanfald).
Brinavess must not be given within 30 days of having acute coronary syndrome (a group of heart problems that include unstable angina and heart attacks).
BRINAVESS må ikke gives til patienter, som har fået intravenøse antiarytmika (klasse I og III) mindre end 4 timer før vernakalant (se pkt.
BRINAVESS must not be administered in patients who received intravenous AADs (class I and III) within 4 hours prior to vernakalant (see section 4.3).
BRINAVESS må ikke gives til patienter, som har fået intravenøse antiarytmika (klasse I og III) op til 4 timer før vernakalant (se pkt.
BRINAVESS must not be administered in patients who received intravenous AADs (class I and III) within 4 hours prior to vernakalant (see section 4.3).
Brinavess skal administreres af en kvalificeret sundhedsfaglig person i et miljø, hvor patientens hjerte kan overvåges effektivt.
Brinavess should be given by a qualified healthcare professional in a setting where the patient’s heart can be properly monitored.
Brinavess skal anvendes til behandling af flimren, som er startet inden for de seneste syv dage, eller inden for de seneste tre dage, hvis patienten for nylig har gennemgået en hjerteoperation.
Brinavess is to be used for fibrillation that has started within the last seven days, or within the last three days if the patient had recently had heart surgery.
BRINAVESS skal indgives som intravenøs infusion under monitorering i et klinisk miljø, der er egnet til konvertering.
BRINAVESS should be administered by intravenous infusion in a monitored clinical setting appropriate for cardioversion.
BRINAVESS skal indgives som intravenøs infusion under monitorering i et klinisk miljø, der er egnet til konvertering.
BRINAVESS should be administered in a monitored clinical setting appropriate for cardioversion by a well-qualified healthcare professional.
Brinavess vernakalanthydrochlorid
Brinavess vernakalant hydrochloride
Brintellix 10 mg filmovertrukne tabletter EU/1/13/891/008-017
Brintellix 10 mg film-coated tablets EU/1/13/891/008-017 EU/1/13/891/039
Brintellix 10 mg filmovertrukne tabletter: vortioxetine
Brintellix 10 mg film-coated tablets vortioxetine
Brintellix 20 mg filmovertrukne tabletter vortioxetine
Brintellix 20 mg film-coated tablets Vortioxetine
Brintellix 20 mg filmovertrukne tabletter: vortioxetine
Brintellix 20 mg film-coated tablets vortioxetine
Brintellix 5 mg filmovertrukne tabletter EU/1/13/891/001-007 EU/1/13/891/037-038
Brintellix 5 mg film-coated tablets EU/1/13/891/001-007 EU/1/13/891/037-038
Brintellix 5 mg filmovertrukne tabletter: vortioxetine
Brintellix 5 mg film-coated tablets vortioxetine
Brintellix bør anvendes med forsigtighed til patienter med mani/hypomani i anamnesen og seponeres, hvis patienten er på vej ind i en manisk fase.
Brintellix should be used with caution in patients with a history of mania/hypomania and should be discontinued in any patient entering a manic phase.
Brintellix bør ikke anvendes under graviditet, medmindre kvindens kliniske tilstand kræver behandling med vortioxetin.
Brintellix should not be used during pregnancy unless the clinical condition of the woman requires treatment with vortioxetine.
Brintellix orale dråber, opløsning, udleveres i 20 ml ravfarvede glasflasker.
Brintellix oral drops, solution, are available in 20 ml amber glass bottles.
Brintellix’ sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of Brintellix in children and adolescents aged less than 18 years have not been established.
Brinzolamid + Brimonidin Middela
Brinzolamide + Brimonidine Meana
Brinzolamid er en karboanhydrasehæmmer, der selvom den indgives topikalt, absorberes systemisk.
Brinzolamide is a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically.
Brinzolamid er en stærk hæmmer af human karboanhydrase II (CA-II), det fremherskende isoenzym i øjet.
Brinzolamide is a potent inhibitor of human carbonic anhydrase II (CA-II), the predominant iso- enzyme in the eye.
Brinzolamid metaboliseres af cytokrom P450 i leveren, især CYP3A4, CYP2A6, CYP2B6, CYP2C8 og CYP2C9.
Brinzolamide is metabolized by hepatic cytochrome P450 isozymes, specifically CYP3A4, CYP2A6, CYP2B6, CYP2C8 and CYP2C9.
Brinzolamid og
Brinzolamide and
Brinzolamid og N-Desethyl-brinzolamid er den prædominante komponent fundet i urinen sammen med mindre koncentrationer af N-desmethoxypropyl og desmethyl metabolitter.
Brinzolamide and N-desethylbrinzolamide are the predominant components in the urine along with trace levels (<1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Brinzolamid og timolol absorberes systemisk.
Brinzolamide and timolol are absorbed systemically.
Brinzolamid tilhører en gruppe af lægemidler, der kaldes ”karboanhydrasehæmmere”, og brimonidintartrat en gruppe af lægemidler, der kaldes ”alfa-2-adrenerge receptoragonister”.
Brinzolamide belongs to a group of medicines called ‘carbonic anhydrase inhibitors’ and brimonidine tartrate belongs to a group of medicines called ‘alpha-2 adrenergic receptor agonists’.
Brinzolamid var teratogent i rotter, men ikke i kaniner, efter systemisk administration.
Brinzolamide was teratogenic in rats, but not rabbits, following systemic administration.
Brinzolamid-komponenten i SIMBRINZA udskilles overvejende renalt, hvorfor SIMBRINZA øjendråber er kontraindiceret hos denne patientgruppe (se pkt.
Since the brinzolamide component of SIMBRINZA and its metabolite are excreted predominantly by the kidney, SIMBRINZA is contraindicated in such patients (see sections 4.3).
Brinzolamid/brimonidintartrat
Brinzolamide/brimonidine tartrate
Brinzolamid/Timolol
Brinzolamide/Timolol
Brissel
Thymus
Bristning af milten
rupture of the spleen
Bristol-Myers Squibb Company 6000 Thompson Road, East Syracuse Ney York 13057 – U.S.A.
Bristol-Myers Squibb Company 6000 Thompson Road, East Syracuse New York 13057 – U.S.A.
Bristol-Myers Squibb Pharma EEIG
Bristol Myers Squibb Pharma EEIG
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park
Bristol Myers Squibb Pharma EEIG Uxbridge Business Park
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park
Marketing Authorisation Holder: Bristol Myers Squibb Pharma EEIG Uxbridge Business Park
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park
Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso 03012 Anagni (FR) - Italien
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso 03012 Anagni (FR) - Italy
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso I-03012 Anagni-Frosinone Italien
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso I-03012 Anagni-Frosinone Italy
Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, 03012 Anagni (FR), Italien
Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, 03012 Anagni (FR), Italy
Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middelsex UB8 1DH
Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH
Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH - Storbritannien
Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH - United Kingdom
Bristol–Myers Squibb Company 6000 Thompson Road
Bristol-Myers Squibb Company 6000 Thompson Road
Bristol–Myers Squibb Pharma EEIG Uxbridge Business Park
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park
Bristol–Myers Squibb Pharma EEIG Uxbridge Business Park – Sanderson Road Uxbridge UB8 1DH – Storbritannien
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park - Sanderson Road Uxbridge UB8 1DH - United Kingdom
Bristol–Myers Squibb S.r.l.
Bristol-Myers Squibb S.r.l.
bRitonavir oral opløsning cRitonavir oral opløsning eller kapsler/tabletter
bRitonavir oral solution cRitonavir oral solution or capsule/tablet
Británia/Iso-Britannia/Storbritannien
/Velika Britanija/Vel’ká Británia/Iso- Britannia/Storbritannien Tel/Tlf/Tηλ/Sími/Puh: +44 1256 894 894
BRIVANESS har en lille til moderat indflydelse på evnen til at føre motorkøretøj og betjene maskiner.
BRINAVESS has a minor to moderate influence on the ability to drive and use machines.
Brivaracetam 50 mg/dag eller 150 mg/dag påvirkede ikke AUC for midazolam (metaboliseres af CYP3A4).
Brivaracetam given 50 or 150 mg/day did not affect the AUC of midazolam (metabolised by CYP3A4).
Brivaracetam blev vurderet hos 152 forsøgspersoner i alderen 1 måned til 16 år i et åbent korterevarende farmakokinetisk studie og et igangværende åbent forlængelsesstudie (se pkt.
Brivaracetam was evaluated in these patients in short term open label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).
Brivaracetam blev vurderet hos 152 forsøgspersoner i alderen 1 måned til 16 år i et åbent korterevarende farmakokinetisk studie og et igangværende åbent forlængelsesstudie (se pkt.
Brivaracetam was evaluated in these patients in short term open-label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).
Brivaracetam viser en høj og selektiv affinitet til det synaptiske vesikelprotein 2A (SV2A), som er et transmembrant glycoprotein, som findes på præsynaptisk niveau i neuroner og endokrine celler.
Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells.
Brivaracetams farmakokinetik blev ikke påvirket af race (kaukasisk, asiatisk) i signifikant grad i en farmakokinetisk populationsmodellering fra epilepsipatienter.
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, , Asian) in a population pharmacokinetic modeling from epilepsy patients.
Brivaracetams sikkerhed og virkning hos børn under 16 år er endnu ikke klarlagt.
The safety and efficacy of brivaracetam in children aged less than 16 years have not yet been established.
Brivaracetams virkning på andre lægemidler
Effects of brivaracetam on other medicinal products
Briviact 10 mg er hvide til gråhvide, runde, filmovertrukne tabletter med en diameter på 6,5 mm og er præget med ”u10” på den ene side.
Briviact 10 mg are white to off-white, round, film-coated tablets of 6.5 mm in diameter and debossed with ‘u10’ on one side.
Briviact 10 mg filmovertrukne tabletter brivaracetam
Briviact 10 mg film-coated tablets brivaracetam
Briviact 10 mg filmovertrukne tabletter Polyvinylalkohol
Briviact 10 mg film-coated tablets Polyvinyl alcohol
Briviact 10 mg tabletter brivaracetam
Briviact 10 mg tablets brivaracetam
Briviact 10 mg/ml (Kun for ydre karton)
Briviact 10 mg/ml (Only for outer carton)
Briviact 10 mg/ml injektions-/infusionsvæske, opløsning
Briviact 10 mg/ml solution for injection/infusion
Briviact 10 mg/ml injektions-/infusionsvæske, opløsning brivaracetam
Briviact 10 mg/ml solution for injection/infusion brivaracetam
Briviact 10 mg/ml injektions-/infusionsvæske, opløsning er en klar, farveløs, steril opløsning.
Briviact 10 mg/ml solution for injection/infusion is a clear, colourless, sterile solution.
Briviact 10 mg/ml oral opløsning
Briviact 10 mg/ml oral solution
Briviact 10 mg/ml oral opløsning brivaracetam
Briviact 10mg/ml oral solution brivaracetam
Briviact 10 mg/ml oral opløsning er en let tyktflydende, klar, farveløs til gullig væske.
Briviact 10 mg/ml oral solution is slightly viscous, clear, colourless to yellowish liquid.
Briviact 100 mg er grøn-grå, ovale, filmovertrukne tabletter, der måler 14,5 mm x 8,1 mm og er præget med ”u100” på den ene side.
Briviact 100 mg are green-grey, oval, film-coated tablets of 14.5 mm x 8.1 mm and debossed with ‘u100’ on one side.
Briviact 100 mg filmovertrukne tabletter brivaracetam
Briviact 100 mg film-coated tablets brivaracetam
Briviact 100 mg tabletter brivaracetam
Briviact 100 mg tablets brivaracetam
Briviact 25 mg er grå, ovale, filmovertrukne tabletter, der måler 8,9 mm x 5,0 mm og er præget med ”u25” på den ene side.
Briviact 25 mg are grey, oval, film-coated tablets of 8.9 mm x 5.0 mm and debossed with ‘u25’ on one side.
Briviact 25 mg filmovertrukne tabletter brivaracetam
Briviact 25 mg film-coated tablets brivaracetam
Briviact 25 mg filmovertrukne tabletter Polyvinylalkohol
Briviact 25 mg film-coated tablets Polyvinyl alcohol
Briviact 25 mg tabletter brivaracetam
Briviact 25 mg tablets brivaracetam
Briviact 300 ml glasflasken er pakket i en papkarton, der indeholder en 10 ml oral sprøjte og en adapter til sprøjten.
The 300 ml glass bottle of Briviact is packed in a cardboard box containing a 10 ml oral syringe and an adaptor for the syringe.
Briviact 50 mg er gule, ovale, filmovertrukne tabletter, der måler 11,7 mm x 6,6 mm og er præget med ”u50” på den ene side.
Briviact 50 mg are yellow, oval, film-coated tablets of 11.7 mm x 6.6 mm and debossed with ‘u50’ on one side.
Briviact 50 mg filmovertrukne tabletter brivaracetam
Briviact 50 mg film-coated tablets brivaracetam
Briviact 50 mg tabletter brivaracetam
Briviact 50 mg tablets brivaracetam
Briviact 75 mg er lilla, ovale, filmovertrukne tabletter, der måler 13,0 mm x 7,3 mm og er præget med ”u75” på den ene side.
Briviact 75 mg are purple, oval, film-coated tablets of 13.0 mm x 7.3 mm and debossed with ‘u75’ on one side.
Briviact 75 mg filmovertrukne tabletter brivaracetam
Briviact 75 mg film-coated tablets brivaracetam
Briviact 75 mg filmovertrukne tabletter Polyvinylalkohol
Briviact 75 mg film-coated tablets Polyvinyl alcohol
Briviact 75 mg tabletter brivaracetam
Briviact 75 mg tablets brivaracetam
Briviact anvendes hos voksne og unge over 16 år til behandling af en bestemt type epilepsi, som kendetegnes ved forekomsten af ”partielle anfald” med eller uden generalisering.
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalisation’.
Briviact anvendes hos voksne og unge over 16 år til behandling af en bestemt type epilepsi, som kendetegnes ved forekomsten af ”partielle anfald” med eller uden generalisering.
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalization’.
Briviact er ikke beregnet til anvendelse hos børn og unge under 16 år.
Briviact is not recommended for use in children and young people under 16 years of age.
Briviact er indiceret som tillægsbehandling til behandling af partielle anfald med eller uden sekundær generalisering hos voksne og unge patienter over 16 år med epilepsi.
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Briviact er mere effektivt end virkningsløs behandling (placebo) til at reducere anfald.
Briviact is more effective than placebo (a dummy treatment) at reducing seizures.
Briviact er til langtidsbehandling – fortsæt med at tage Briviact, indtil lægen siger, at De skal stoppe behandlingen.
Briviact is a long term treatment – keep taking Briviact until your doctor tells you to stop.
Briviact fås som tabletter (10, 25, 50, 75 og 100 mg), oral opløsning (10 mg/ml) og injektions- eller infusionsvæske (til drop) i en vene (10 mg/ml).
Briviact is available as tablets (10, 25, 50, 75 and 100 mg), an oral solution (10 mg/ml) and a solution for injection or infusion (drip) into a vein (10 mg/ml).
Briviact indeholder methylparahydroxybenzoat, natrium og sorbitol
Briviact oral solution contains methyl parahydroxybenzoate, sodium and sorbitol
Briviact injektions-/infusionsvæske, opløsning anvendes i kortere perioder, når De ikke kan tage Briviact gennem munden.
Briviact solution for injection/infusion is used for a short amount of time when you cannot take Briviact orally.